Seeking Alpha

Alnylam (ALNY -0.7%) announces positive results from a pre-clinical ex vivo study, which takes...

Alnylam (ALNY -0.7%) announces positive results from a pre-clinical ex vivo study, which takes place outside the organism, that could lead to the development of improved cellular vaccines for cancer and chronic viral infections. Alnylam's focus is RNA interference (RNAi), or the study of how genes are turned on and off in cells. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)